微RNA-146a靶向PRKCE以调节甲状腺乳头状瘤进展MicroRNA-146a targets PRKCE to modulate papillary thyroid tumor development.
MicroRNA-146a targets PRKCE to modulate papillary thyroid tumor development.
Abstract
MicroRNAs (miRNAs) are single-stranded non-coding RNAs comprised of approximately 22 nucleotides that suppress gene expression by selectively binding via base-pairing to the complementary 3' untranslated region (3'-UTR) of messenger RNA (mRNA) transcripts. Protein kinase C epsilon (PKCε) is an important modulating member of the transducing Ras/Raf-1 signal pathway; a computational search revealed miR-146a putatively binds to the 3' UTR of the PRKCE gene, thus decreasing PKCε expression. Moreover, PKCε inhibits mitochonodrial apoptosis and is associated with the Bcl family. However, it has been previously reported that miR-146a expression in papillary thyroid carcinoma (PTC) is slightly elevated. Thus, we hypothesized that because miR-146a expression depends upon NF-κB activation and NF-κB expression is elevated in PTC, miR-146a is potentially up-regulated in PTC via negative feedback of NF-κB, thus suppressing PKCε expression. In this study, we investigated whether overexpression of miR-146a, a tumor-suppressing-miR, in PTC cells decreases cell survival and induces apoptosis. Luciferase reporter assay analysis confirmed the direct binding of miR-146a and PRKCE 3' UTR. Specific overexpression of exogenous miR-146a significantly decreased PKCε levels in PTC cell line NPA-187 and increased apoptosis. Additionally, using stably expressing miR-146a thyroid carcinoma cells to establish subcutaneous tumors, the tumor growth exhibited significant inhibition. Our study confirmed the tumor-suppressing role of miR-146a in thyroid carcinoma cells and contributes to knowledge regarding modulation of Ras/Raf-1 signal transduction and apoptosis via PKCε targeted by miR-146a in PTC; moreover, our findings confirmed that miR-146a is involved in the feedback system of the classical NF-κB signal pathway in PTC. © 2013 Wiley Periodicals, Inc.
copyright©金宝搏网站登录技巧 版权所有,未经许可不得复制、转载或镜像
京ICP证120392号 京公网安备110105007198 京ICP备10215607号-1 (京)网药械信息备字(2022)第00160号